- $99.56m
- $40.32m
- $237.26m
Brief: Vaxart Inc - On Feb 14 Got Letter From Nasdaq That Co Regained Compliance With Minimum Bid Price Requirement
Brief: Vaxart Says Nasdaq Notified Co It Was Eligible Until July 15, 2024, To Regain Compliance With Bid Price Requirement
Brief: Vaxart Awarded ASPR Contract By U.S. Government
Brief: Vaxart Announces Last Subject Dosed In Phase 1 Trial Of Its Norovirus Vaccine Candidate In Lactating Mothers
Vaxart Inc reports results for the quarter ended in September - Earnings Summary
Brief: Vaxart Q3 Net Income USD -17.4 Million
Brief: Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
Vaxart Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Vaxart Announces Topline Data From The Phase 2 Challenge Study Of Its Monovalent Norovirus Vaccine Candidate
Vaxart Inc reports results for the quarter ended in June - Earnings Summary
Brief: Vaxart Q2 Net Income USD -22.55 Million
Vaxart Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Vaxart Says On July 21, Co Got Written Notice From Nasdaq That Co Is Not In Compliance With Minimum Bid Price Requirement
Brief: Vaxart Announces Positive Preliminary Topline Data From Dose-Ranging Phase 2 Study Of Its Bivalent Norovirus Vaccine Candidate
Brief: Vaxart Inc Says Shareholders Voted On All Proposals In Alignment With Co's Recommendations From 2023 Proxy Statement
U.S. STOCKS ON THE MOVE-Biogen, Phoenix Motor, Mastercard
U.S. STOCKS ON THE MOVE-Energy sector, Affirm, Stitch Fix
Biotech firm Vaxart falls after announcing $15 mln stock offering
Brief: Vaxart Inc Announces Proposed Public Offering Of Common Stock